A new trading day began on Tuesday, with Editas Medicine Inc (NASDAQ: EDIT) stock price up 5.56% from the previous day of trading, before settling in for the closing price of $2.52. EDIT’s price has ranged from $0.91 to $4.54 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -1.48%. Meanwhile, its annual earnings per share averaged 29.84%. With a float of $89.37 million, this company’s outstanding shares have now reached $93.26 million.
Editas Medicine Inc (EDIT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.62%, while institutional ownership is 46.64%. The most recent insider transaction that took place on Sep 03 ’25, was worth 1,843. In this transaction EVP, CHIEF SCIENTIFIC OFFICER of this company sold 710 shares at a rate of $2.60, taking the stock ownership to the 69,490 shares. Before that another transaction happened on Sep 03 ’25, when Company’s SVP, Chief Financial Officer sold 458 for $2.60, making the entire transaction worth $1,189. This insider now owns 16,369 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.55 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.70% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Here are Editas Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.38, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -1.09 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 2.2 million, which is a drop from its year-to-date volume of 2.82 million. As of the previous 9 days, the stock’s Stochastic %D was 21.26%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 25.43%, which indicates a significant increase from 21.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.23 in the past 14 days, which was lower than the 0.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.23, while its 200-day Moving Average is $2.25. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $2.75. Second resistance stands at $2.83. The third major resistance level sits at $3.00. If the price goes on to break the first support level at $2.50, it is likely to go to the next support level at $2.33. Should the price break the second support level, the third support level stands at $2.25.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
With a market capitalization of 259.67 million, the company has a total of 89,920K Shares Outstanding. Currently, annual sales are 32,310 K while annual income is -237,090 K. The company’s previous quarter sales were 3,580 K while its latest quarter income was -53,240 K.
